National and Kapodistrian University of Athens
Διερεύνηση οικογενειών με βεβαρημένο οικογενειακό ιστορικό καρκίνου με αρνητική ανάλυση πάνελ 36 γονιδίων χρησιμοποιώντας exome sequencing και polygenic risk score (PRS)
Abstract
dc:descriptionIntroduction: Hereditary cancer accounts for approximately 5–10% of all cancer cases. Over the past decade, technological advancements, particularly the advent of Next Generation Sequencing (NGS), have enabled the analysis of many more genes associated with hereditary cancer predisposition. The aim of this doctoral thesis is: A) to retrospectively evaluate the clinical utility of polygenic risk score (PRS) estimation in the development of breast cancer, using a cohort of patients already diagnosed with breast cancer, and B) to potentially identify new genetic loci associated with hereditary breast cancer through whole-exome sequencing (WES).Materials and Methods: Between 2020 and 2023, a total of 8,261 individuals were referred for multigene panel testing of 52 genes using NGS at the Genekor Medical S.A. laboratory. Subsequently, among the 4,641 patients with breast cancer, PRS analysis was conducted in 105 individuals with known results from targeted genetic testing, analyzing 577,113 single nucleotide polymorphisms (SNPs). Additionally, in order to clarify the genetic cause of breast cancer, WES analysis was performed on 85 women (excluding those positive for a high-penetrance gene).Results:20% of the individuals tested carried a pathogenic variant. Specifically, 54.8% of patients had a pathogenic variant in a clinically significant gene (including BRCA1, BRCA2, PALB2, RAD51C, PMS2, CDKN2A, MLH1, MSH2, TP53, MSH6, APC, RAD51D, PTEN, RET, CDH1, MEN1, and VHL). Among the various types of pathogenic variants detected, a significant proportion (6.52%) represented large genomic rearrangements (Copy Number Variations - CNVs).The PRS analysis showed a significant difference in the distribution of PRS percentiles, indicating a higher risk of developing breast cancer in the study group compared to the general population. Higher PRS values were observed in women who developed the disease at a younger age and those with a family history of breast cancer. Among patients with a detected pathogenic variant, lower PRS values were observed, as the risk of developing breast cancer was primarily due to monogenic etiology. Through WES analysis, the following findings were identified:CTC1: c.880C>T, p.(Gln294*)MLH3: c.405del, p.(Asp136Metfs*2)PPM1D: c.1426_1430del, p.(Glu476Leufs*3)SDHB: c.395A>G, p.(His132Arg) Conclusions: Comprehensive genetic testing is essential, as it can provide information relevant to the clinical management of individuals carrying pathogenic variants. Moreover, the calculation of PRS is particularly useful in women with a family history of breast cancer when no monogenic etiology is identified through NGS.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsoulos, Nikolaos
- Τσούλος, Νικόλαος
Subjects
dc:subject × 13Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58915